Synlogic, Inc.
(NASDAQ : SYBX)

( )
SYBX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.69%183.171.3%$509.31m
CELGCelgene Corporation
-0.84%92.411.3%$442.42m
ARRYArray BioPharma Inc.
-0.20%46.128.1%$426.45m
GILDGilead Sciences, Inc.
-2.63%66.680.9%$400.32m
BIIBBiogen Inc.
-0.92%238.071.3%$377.86m
ILMNIllumina, Inc.
-0.48%356.373.5%$303.03m
REGNRegeneron Pharmaceuticals, Inc.
-2.50%305.082.6%$243.93m
VRTXVertex Pharmaceuticals Incorporated
-1.38%177.661.9%$210.42m
ALXNAlexion Pharmaceuticals, Inc.
0.15%125.342.0%$206.43m
EXASExact Sciences Corporation
1.20%112.7924.1%$187.08m
AAgilent Technologies, Inc.
-0.46%72.181.6%$154.39m
BMRNBioMarin Pharmaceutical Inc.
-1.04%82.954.3%$124.74m
SRPTSarepta Therapeutics, Inc.
3.37%128.3414.7%$119.55m
INCYIncyte Corporation
-2.26%85.632.5%$112.69m
MRTXMirati Therapeutics Inc.
-2.09%100.012.5%$104.17m

Company Profile

Synlogic, Inc. is a clinical-stage biopharmaceutical company, which engages in drug discovery and development of synthetic biotic medicines. It focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.